Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Unknown 2Terminated 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 9Gastrointestinal 5Thoracic 4Breast 4Genitourinary 3Dermatologic 3Head & Neck 2CNS 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 2Neoplasms 2Wilms Tumor 1Sarcoma 1Neuroblastoma 1Lung Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Adenoviridae Infections 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Vaccines × Genitourinary × Clear all
NCT02362464 2024-12-10

Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
14 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

NCT03384316 2020-09-09

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 18 charts
BreastGastrointestinalGenitourinaryThoracic

Adenoviridae Infections, Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasms, Prostatic Neoplasms

NCT00405327 2017-11-06

A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation

University of Michigan Rogel Cancer Center

Phase 2 Completed
16 enrolled
CNSGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡